These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33894670)

  • 21. EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes.
    Hernando H; Gelato KA; Lesche R; Beckmann G; Koehr S; Otto S; Steigemann P; Stresemann C
    Mol Cancer Ther; 2016 Feb; 15(2):287-98. PubMed ID: 26590165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polycomb PHF19 binds H3K36me3 and recruits PRC2 and demethylase NO66 to embryonic stem cell genes during differentiation.
    Brien GL; Gambero G; O'Connell DJ; Jerman E; Turner SA; Egan CM; Dunne EJ; Jurgens MC; Wynne K; Piao L; Lohan AJ; Ferguson N; Shi X; Sinha KM; Loftus BJ; Cagney G; Bracken AP
    Nat Struct Mol Biol; 2012 Dec; 19(12):1273-81. PubMed ID: 23160351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PHF19 before and post induction treatment possess favorable potency of reflecting treatment response to protease inhibitors, event-free survival, and overall survival in multiple myeloma patients.
    An H; Chen S; Zhang X; Ke S; Ke J; Lu Y
    Hematology; 2024 Dec; 29(1):2331389. PubMed ID: 38511642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8
    Ji Y; Fioravanti J; Zhu W; Wang H; Wu T; Hu J; Lacey NE; Gautam S; Le Gall JB; Yang X; Hocker JD; Escobar TM; He S; Dell'Orso S; Hawk NV; Kapoor V; Telford WG; Di Croce L; Muljo SA; Zhang Y; Sartorelli V; Gattinoni L
    Nat Commun; 2019 May; 10(1):2157. PubMed ID: 31089138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PICOT binding to the polycomb group protein, EED, alters H3K27 methylation at the MYT1 PRC2 target gene.
    Pandya P; Pasvolsky R; Babichev Y; Braiman A; Witte S; Altman A; Isakov N
    Biochem Biophys Res Commun; 2019 Feb; 509(2):469-475. PubMed ID: 30595380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-195-5p acts as an anti-oncogene by targeting PHF19 in hepatocellular carcinoma.
    Xu H; Hu YW; Zhao JY; Hu XM; Li SF; Wang YC; Gao JJ; Sha YH; Kang CM; Lin L; Huang C; Zhao JJ; Zheng L; Wang Q
    Oncol Rep; 2015 Jul; 34(1):175-82. PubMed ID: 25955388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease.
    Mason MJ; Schinke C; Eng CLP; Towfic F; Gruber F; Dervan A; White BS; Pratapa A; Guan Y; Chen H; Cui Y; Li B; Yu T; Chaibub Neto E; Mavrommatis K; Ortiz M; Lyzogubov V; Bisht K; Dai HY; Schmitz F; Flynt E; Dan Rozelle ; Danziger SA; Ratushny A; ; Dalton WS; Goldschmidt H; Avet-Loiseau H; Samur M; Hayete B; Sonneveld P; Shain KH; Munshi N; Auclair D; Hose D; Morgan G; Trotter M; Bassett D; Goke J; Walker BA; Thakurta A; Guinney J
    Leukemia; 2020 Jul; 34(7):1866-1874. PubMed ID: 32060406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PHF19 activates hedgehog signaling and promotes tumorigenesis in hepatocellular carcinoma.
    Xiaoyun S; Yuyuan Z; Jie X; Yingjie N; Qing X; Yuezhen D; Haiguang X
    Exp Cell Res; 2021 Sep; 406(1):112690. PubMed ID: 34129846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
    Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
    Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PHF19 and Akt control the switch between proliferative and invasive states in melanoma.
    Ghislin S; Deshayes F; Middendorp S; Boggetto N; Alcaide-Loridan C
    Cell Cycle; 2012 Apr; 11(8):1634-45. PubMed ID: 22487681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Polycomb-associated factor PHF19 controls hematopoietic stem cell state and differentiation.
    Vizán P; Gutiérrez A; Espejo I; García-Montolio M; Lange M; Carretero A; Lafzi A; de Andrés-Aguayo L; Blanco E; Thambyrajah R; Graf T; Heyn H; Bigas A; Di Croce L
    Sci Adv; 2020 Aug; 6(32):eabb2745. PubMed ID: 32821835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma.
    Rizk M; Rizq O; Oshima M; Nakajima-Takagi Y; Koide S; Saraya A; Isshiki Y; Chiba T; Yamazaki S; Ma A; Jin J; Iwama A; Mimura N
    Cancer Sci; 2019 Dec; 110(12):3695-3707. PubMed ID: 31571328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma.
    Johnson TS; Sudha P; Liu E; Becker N; Robertson S; Blaney P; Morgan G; Chopra VS; Dos Santos C; Nixon M; Huang K; Suvannasankha A; Zaid MA; Abonour R; Walker BA
    Nat Commun; 2024 May; 15(1):4144. PubMed ID: 38755140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.
    Kim SH; Yang WI; Min YH; Ko YH; Yoon SO
    Tumour Biol; 2016 Feb; 37(2):2037-47. PubMed ID: 26337274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
    Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
    Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
    [No Abstract]   [Full Text] [Related]  

  • 36. [EZH2 is therapeutic target for personalized treatment in multiple myeloma].
    Herviou L; Cavalli G; Moreaux J
    Bull Cancer; 2018 Sep; 105(9):804-819. PubMed ID: 30041976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inner workings and regulatory inputs that control Polycomb repressive complex 2.
    O'Meara MM; Simon JA
    Chromosoma; 2012 Jun; 121(3):221-34. PubMed ID: 22349693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peritoneal Modulators of EZH2-miR-155 Cross-Talk in Endometriosis.
    Brunty S; Ray Wright K; Mitchell B; Santanam N
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polycomb-like proteins link the PRC2 complex to CpG islands.
    Li H; Liefke R; Jiang J; Kurland JV; Tian W; Deng P; Zhang W; He Q; Patel DJ; Bulyk ML; Shi Y; Wang Z
    Nature; 2017 Sep; 549(7671):287-291. PubMed ID: 28869966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High PHD Finger Protein 19 (PHF19) expression predicts poor prognosis in colorectal cancer: a retrospective study.
    Li P; Sun J; Ruan Y; Song L
    PeerJ; 2021; 9():e11551. PubMed ID: 34141488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.